Countable Labs and Promega announced a comarketing agreement combining Promega’s automated Maxwell nucleic acid extraction workflow with Countable Labs’ single-molecule PCR for rare variant detection. The partnership will deliver a unified solution for DNA and RNA quantification built around a compact, benchtop extraction step followed by compartmentalized single-molecule amplification. Countable said the combined approach is intended to help with translational research and diagnostics use cases, including minimal residual disease monitoring and liquid biopsy workflows. The companies reported preliminary in-house performance using a multiplexed KRAS assay, reaching 0.08% mutant allele frequency without compromising multiplex sensitivity. The deal extends Promega’s role in companion diagnostics-adjacent workflows, following the company’s FDA clearance for its first companion diagnostic test last year. For Countable, the agreement comes after the company closed a $26 million financing round last month, reinforcing continued investor and partner interest in single-molecule assay formats. In a market where rare variant sensitivity is often limited by pre-analytical steps, the combined workflow targets end-to-end robustness from sample prep through detection.